Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2017-2019

ABSTRACT

Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by eosinophilic inflammation as well as P-gp overexpression. A previous trial of oral Verapamil showed preliminary efficacy for the treatment of CRSwNP. The goal of this study is to evaluate the safety and efficacy of intranasal Verapamil in CRSwNP. Detailed Description CRSwNP is a prevalent disease associated with major direct and indirect costs. Acute and Chronic Rhinosinusitis are estimated to affect up to 16% of the US population. They account for approximately 11 million or 1% of all office visits per year in the US and are the most common cause for antibiotic prescriptions in the community. CRS alone impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The subset of patients in Europe with CRSwNP has been estimated to be between 2 and 4.3% and is thought to be similar in the US. This population remains one of the most challenging subgroups of CRS to manage effectively. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp). Studies by the investigator's group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target. The investigator's group therefore undertook a randomized, double-blind, placebo-controlled trial to test the efficacy of low dose oral Verapamil HCl, a known first generation P-gp inhibitor, for the treatment of CRSwNP. Our findings demonstrated significant efficacy in both of the primary and secondary endpoints with no significant side effects. However, a logistic regression analysis revealed two important relationships between baseline characteristics and efficacy. First, patients with elevated BMI had significantly lower improvements in the Sinonasal Outcome Test (SNOT-22) (p=0.01). The second is that patients with the highest total mucus P-gp levels experienced less benefit(p=0.01). While Verapamil HCl has significant potential for the treatment of CRSwNP through P-gp inhibition, higher doses must be achieved to extend the effect to patients with elevated BMIs and the highest levels of P-gp expression. As increasing oral dosing could result in cardiac side effects, topical delivery represents a promising alternative. As exosome bound P-gp may be more stable and representative of disease state than total mucus P-gp concentration, exosomal P-gp demands further exploration as a novel biomarker of disease severity and drug response. More... »

URL

https://clinicaltrials.gov/show/NCT03102190

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3048", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by eosinophilic inflammation as well as P-gp overexpression. A previous trial of oral Verapamil showed preliminary efficacy for the treatment of CRSwNP. The goal of this study is to evaluate the safety and efficacy of intranasal Verapamil in CRSwNP.\n\nDetailed Description\nCRSwNP is a prevalent disease associated with major direct and indirect costs. Acute and Chronic Rhinosinusitis are estimated to affect up to 16% of the US population. They account for approximately 11 million or 1% of all office visits per year in the US and are the most common cause for antibiotic prescriptions in the community. CRS alone impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The subset of patients in Europe with CRSwNP has been estimated to be between 2 and 4.3% and is thought to be similar in the US. This population remains one of the most challenging subgroups of CRS to manage effectively. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp). Studies by the investigator's group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target. The investigator's group therefore undertook a randomized, double-blind, placebo-controlled trial to test the efficacy of low dose oral Verapamil HCl, a known first generation P-gp inhibitor, for the treatment of CRSwNP. Our findings demonstrated significant efficacy in both of the primary and secondary endpoints with no significant side effects. However, a logistic regression analysis revealed two important relationships between baseline characteristics and efficacy. First, patients with elevated BMI had significantly lower improvements in the Sinonasal Outcome Test (SNOT-22) (p=0.01). The second is that patients with the highest total mucus P-gp levels experienced less benefit(p=0.01). While Verapamil HCl has significant potential for the treatment of CRSwNP through P-gp inhibition, higher doses must be achieved to extend the effect to patients with elevated BMIs and the highest levels of P-gp expression. As increasing oral dosing could result in cardiac side effects, topical delivery represents a promising alternative. As exosome bound P-gp may be more stable and representative of disease state than total mucus P-gp concentration, exosomal P-gp demands further exploration as a novel biomarker of disease severity and drug response.", 
    "endDate": "2019-07-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT03102190", 
    "keywords": [
      "clinical trial", 
      "verapamil", 
      "chronic rhinosinusitis", 
      "nasal polyp", 
      "calcium channel blocker", 
      "inflammation", 
      "tissue", 
      "CRSwNP", 
      "eosinophilic inflammation", 
      "overexpression", 
      "previous trial", 
      "preliminary efficacy", 
      "safety", 
      "efficacy", 
      "prevalent disease", 
      "direct and indirect cost", 
      "US population", 
      "office visit", 
      "US", 
      "antibiotic prescription", 
      "Residence Characteristic", 
      "Cr", 
      "american", 
      "healthcare expenditure", 
      "subset", 
      "patient", 
      "Europe", 
      "population", 
      "subgroup", 
      "Recent evidence", 
      "epithelial cell", 
      "primary driver", 
      "dysregulated immune response", 
      "Bodily Secretion", 
      "helper T cell", 
      "Th2", 
      "cytokine", 
      "local immune response", 
      "cytokine secretion", 
      "efflux", 
      "P-Glycoprotein", 
      "Mucous Membrane", 
      "polarizing", 
      "target", 
      "placebo-controlled trial", 
      "low dose", 
      "first generation", 
      "significant efficacy", 
      "primary and secondary endpoint", 
      "significant side effect", 
      "logistic regression analysis", 
      "important relationship", 
      "baseline characteristic", 
      "BMI", 
      "improvement", 
      "mucus", 
      "less benefit", 
      "inhibition", 
      "high dose", 
      "high level", 
      "P-gp expression", 
      "oral dosing", 
      "side effect", 
      "topical delivery", 
      "exosomes", 
      "disease state", 
      "demand", 
      "exploration", 
      "novel biomarkers", 
      "disease severity", 
      "drug response"
    ], 
    "name": "Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT03102190"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00024.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.39479.30", 
        "type": "Organization"
      }
    ], 
    "startDate": "2017-06-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1111/head.12145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002529252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/alr.21072", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003754472"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1253/circj.cj-09-0467", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008378333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/moo.0b013e32835bc3f9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009617454"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1398-9995.2005.00688.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017007088"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00011-005-0060-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019965301", 
          "https://doi.org/10.1007/s00011-005-0060-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pupt.2011.11.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039786003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10194-010-0289-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042829743", 
          "https://doi.org/10.1007/s10194-010-0289-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.otohns.2004.10.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045349258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1749-4486.2009.01995.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046850455"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jaci.2016.11.014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074187514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078588337", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT03102190"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT03102190'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT03102190'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT03102190'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT03102190'


 

This table displays all metadata directly associated to this object as RDF triples.

127 TRIPLES      16 PREDICATES      98 URIs      80 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT03102190 schema:about anzsrc-for:3048
2 schema:description Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by eosinophilic inflammation as well as P-gp overexpression. A previous trial of oral Verapamil showed preliminary efficacy for the treatment of CRSwNP. The goal of this study is to evaluate the safety and efficacy of intranasal Verapamil in CRSwNP. Detailed Description CRSwNP is a prevalent disease associated with major direct and indirect costs. Acute and Chronic Rhinosinusitis are estimated to affect up to 16% of the US population. They account for approximately 11 million or 1% of all office visits per year in the US and are the most common cause for antibiotic prescriptions in the community. CRS alone impacts more than 30 million Americans resulting in $6.9 to $9.9 billion in annual healthcare expenditures and $12.8 billion in productivity costs. The subset of patients in Europe with CRSwNP has been estimated to be between 2 and 4.3% and is thought to be similar in the US. This population remains one of the most challenging subgroups of CRS to manage effectively. Recent evidence has focused on the sinonasal epithelial cell as a primary driver of the local dysregulated immune response through secretion of type 2 helper T-cell(Th2) promoting cytokines. While these studies suggest that epithelial cells are capable of orchestrating a local immune response, the mechanisms responsible for regulating cytokine secretion are poorly understood and may be influenced by the efflux function of epithelial P-glycoprotein(P-gp). Studies by the investigator's group have demonstrated that P-gp is overexpressed in the mucosa of patients with Th2 skewed CRS endotypes including CRSwNP and is capable of regulating the secretion of Th2 polarizing cytokines. Together, these findings suggest that P-gp participates in the non-canonical regulation of cytokine secretion within CRSwNP and may thereby represent a druggable target. The investigator's group therefore undertook a randomized, double-blind, placebo-controlled trial to test the efficacy of low dose oral Verapamil HCl, a known first generation P-gp inhibitor, for the treatment of CRSwNP. Our findings demonstrated significant efficacy in both of the primary and secondary endpoints with no significant side effects. However, a logistic regression analysis revealed two important relationships between baseline characteristics and efficacy. First, patients with elevated BMI had significantly lower improvements in the Sinonasal Outcome Test (SNOT-22) (p=0.01). The second is that patients with the highest total mucus P-gp levels experienced less benefit(p=0.01). While Verapamil HCl has significant potential for the treatment of CRSwNP through P-gp inhibition, higher doses must be achieved to extend the effect to patients with elevated BMIs and the highest levels of P-gp expression. As increasing oral dosing could result in cardiac side effects, topical delivery represents a promising alternative. As exosome bound P-gp may be more stable and representative of disease state than total mucus P-gp concentration, exosomal P-gp demands further exploration as a novel biomarker of disease severity and drug response.
3 schema:endDate 2019-07-01T00:00:00Z
4 schema:keywords BMI
5 Bodily Secretion
6 CRSwNP
7 Cr
8 Europe
9 Mucous Membrane
10 P-Glycoprotein
11 P-gp expression
12 Recent evidence
13 Residence Characteristic
14 Th2
15 US
16 US population
17 american
18 antibiotic prescription
19 baseline characteristic
20 calcium channel blocker
21 chronic rhinosinusitis
22 clinical trial
23 cytokine
24 cytokine secretion
25 demand
26 direct and indirect cost
27 disease severity
28 disease state
29 drug response
30 dysregulated immune response
31 efficacy
32 efflux
33 eosinophilic inflammation
34 epithelial cell
35 exosomes
36 exploration
37 first generation
38 healthcare expenditure
39 helper T cell
40 high dose
41 high level
42 important relationship
43 improvement
44 inflammation
45 inhibition
46 less benefit
47 local immune response
48 logistic regression analysis
49 low dose
50 mucus
51 nasal polyp
52 novel biomarkers
53 office visit
54 oral dosing
55 overexpression
56 patient
57 placebo-controlled trial
58 polarizing
59 population
60 preliminary efficacy
61 prevalent disease
62 previous trial
63 primary and secondary endpoint
64 primary driver
65 safety
66 side effect
67 significant efficacy
68 significant side effect
69 subgroup
70 subset
71 target
72 tissue
73 topical delivery
74 verapamil
75 schema:name Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps
76 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT03102190
77 schema:sdDatePublished 2019-03-07T15:27
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher Nf5c724c3a62b4cf5a949319da8b5e3a7
80 schema:sponsor https://www.grid.ac/institutes/grid.39479.30
81 schema:startDate 2017-06-01T00:00:00Z
82 schema:subjectOf sg:pub.10.1007/s00011-005-0060-y
83 sg:pub.10.1007/s10194-010-0289-x
84 https://app.dimensions.ai/details/publication/pub.1078588337
85 https://doi.org/10.1002/alr.21072
86 https://doi.org/10.1016/j.jaci.2016.11.014
87 https://doi.org/10.1016/j.otohns.2004.10.010
88 https://doi.org/10.1016/j.pupt.2011.11.001
89 https://doi.org/10.1097/moo.0b013e32835bc3f9
90 https://doi.org/10.1111/head.12145
91 https://doi.org/10.1111/j.1398-9995.2005.00688.x
92 https://doi.org/10.1111/j.1749-4486.2009.01995.x
93 https://doi.org/10.1253/circj.cj-09-0467
94 schema:url https://clinicaltrials.gov/show/NCT03102190
95 sgo:license sg:explorer/license/
96 sgo:sdDataset clinical_trials
97 rdf:type schema:MedicalStudy
98 Nf5c724c3a62b4cf5a949319da8b5e3a7 schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 anzsrc-for:3048 schema:inDefinedTermSet anzsrc-for:
101 rdf:type schema:DefinedTerm
102 sg:pub.10.1007/s00011-005-0060-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1019965301
103 https://doi.org/10.1007/s00011-005-0060-y
104 rdf:type schema:CreativeWork
105 sg:pub.10.1007/s10194-010-0289-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1042829743
106 https://doi.org/10.1007/s10194-010-0289-x
107 rdf:type schema:CreativeWork
108 https://app.dimensions.ai/details/publication/pub.1078588337 schema:CreativeWork
109 https://doi.org/10.1002/alr.21072 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003754472
110 rdf:type schema:CreativeWork
111 https://doi.org/10.1016/j.jaci.2016.11.014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074187514
112 rdf:type schema:CreativeWork
113 https://doi.org/10.1016/j.otohns.2004.10.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045349258
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1016/j.pupt.2011.11.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039786003
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1097/moo.0b013e32835bc3f9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009617454
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1111/head.12145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002529252
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1111/j.1398-9995.2005.00688.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1017007088
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1111/j.1749-4486.2009.01995.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1046850455
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1253/circj.cj-09-0467 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008378333
126 rdf:type schema:CreativeWork
127 https://www.grid.ac/institutes/grid.39479.30 schema:Organization
 




Preview window. Press ESC to close (or click here)


...